We demonstrated here that CDK7 is a novel therapeutic target for pancreatic cancer, which relies on its promotion of cell cycle progression, as well as its interference with DNA damage/DNA damage repair and apoptosis induction. This evidence concerns the gene CDK7 and familial pancreatic carcinoma.